Deutsche Bank AG Boosts Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Deutsche Bank AG grew its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 49.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,398 shares of the biopharmaceutical company's stock after purchasing an additional 41,720 shares during the quarter. Deutsche Bank AG owned about 0.10% of Dynavax Technologies worth $1,614,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its holdings in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Dynavax Technologies in the 4th quarter worth about $71,000. Nisa Investment Advisors LLC increased its stake in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 1,076 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Dynavax Technologies by 68.7% in the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 2,857 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research note on Thursday, April 17th. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities decreased their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, Wall Street Zen lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Stock Down 0.2%

DVAX stock traded down $0.02 during trading on Tuesday, hitting $9.78. 1,332,617 shares of the stock traded hands, compared to its average volume of 2,219,492. Dynavax Technologies Co. has a 1 year low of $9.22 and a 1 year high of $14.63. The firm's 50 day moving average is $11.33 and its two-hundred day moving average is $12.42. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 54.33 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. On average, sell-side analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.